51
|
Belshaw Z, Asher L, Dean RS. The attitudes of owners and veterinary professionals in the United Kingdom to the risk of adverse events associated with using non-steroidal anti-inflammatory drugs (NSAIDs) to treat dogs with osteoarthritis. Prev Vet Med 2016; 131:121-126. [PMID: 27544261 PMCID: PMC5001196 DOI: 10.1016/j.prevetmed.2016.07.017] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 07/26/2016] [Accepted: 07/31/2016] [Indexed: 01/09/2023]
Abstract
Many dogs with osteoarthritis receive NSAIDs for long time periods. The risk of NSAID-related adverse events concerns veterinary surgeons and dog owners. Many strategies are adopted to minimise the risk of these adverse events. These strategies may compromise animal welfare through inadequate analgesia. The evidence base to support these strategies is inadequate and should be addressed.
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed by veterinary surgeons for the treatment of canine osteoarthritis, and affected dogs may receive these drugs for long periods of time. Whilst short term administration of NSAIDs to dogs is linked to adverse events such as gastrointestinal haemorrhage and renal injury, reports of adverse events associated with their long-term administration are limited in the veterinary literature. This study aimed to investigate the attitudes towards the long term use of NSAIDs for canine osteoarthritis held by three groups who manage osteoarthritic dogs in the United Kingdom: dog owners, veterinary surgeons and veterinary nurses. A qualitative methodology was adopted, using semi-structured interviews and focus groups. Thematic analysis of these data identified three themes: awareness of potential risks; recognition of adverse events; and influence of risk perception on the use of NSAIDs. Awareness of, and concern about, the risk of adverse events associated with NSAID administration to dogs with osteoarthritis was high in all groups, with veterinary surgeons being one of a variety of information sources used by owners to acquire this knowledge. Veterinary surgeons described difficulty in recognising, managing and avoiding adverse events associated with NSAIDs. When adverse events occurred, a wide range of management approaches were adopted ranging from a brief drug respite to permanent cessation of administration of any NSAIDs to that dog. Commonly employed approaches to minimise risk included dose reduction and screening blood tests. This study describes a high level of concern about the risks associated with long term NSAID administration to dogs with osteoarthritis and highlights a diverse range of strategies employed to minimise these risks. The evidence base for these strategies is poor, and this may present a risk to animal welfare if the affected dogs are not receiving adequate analgesia. In order to address this, more accurate and comprehensive data must be supplied to both veterinary professionals and owners on the true frequency of adverse events associated with long term administration of veterinary NSAIDs and how best to avoid them.
Collapse
Affiliation(s)
- Zoe Belshaw
- Centre for Evidence-based Veterinary Medicine, School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Loughborough, Leicestershire, LE12 5RD UK.
| | - Lucy Asher
- Centre for Evidence-based Veterinary Medicine, School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Loughborough, Leicestershire, LE12 5RD UK
| | - Rachel S Dean
- Centre for Evidence-based Veterinary Medicine, School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Loughborough, Leicestershire, LE12 5RD UK
| |
Collapse
|
52
|
Parra A, Clares B, Rosselló A, Garduño-Ramírez ML, Abrego G, García ML, Calpena AC. Ex vivo permeation of carprofen from nanoparticles: A comprehensive study through human, porcine and bovine skin as anti-inflammatory agent. Int J Pharm 2016; 501:10-7. [PMID: 26826569 DOI: 10.1016/j.ijpharm.2016.01.056] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2015] [Revised: 01/21/2016] [Accepted: 01/22/2016] [Indexed: 01/05/2023]
Abstract
The purpose of this study was the development of poly(d,l-lactide-co-glycolide) acid (PLGA) nanoparticles (NPs) for the dermal delivery of carprofen (CP). The developed nanovehicle was then lyophilized using hydroxypropyl-β-cyclodextrin (HPβCD) as cryoprotectant. The ex vivo permeation profiles were evaluated using Franz diffusion cells using three different types of skin membranes: human, porcine and bovine. Furthermore, biomechanical properties of skin (trans-epidermal water loss and skin hydration) were tested. Finally, the in vivo skin irritation and the anti-inflammatory efficacy were also assayed. Results demonstrated the achievement of NPs 187.32 nm sized with homogeneous distribution, negatively charged surface (-23.39 mV) and high CP entrapment efficiency (75.38%). Permeation studies showed similar diffusion values between human and porcine skins and higher for bovine. No signs of skin irritation were observed in rabbits. Topically applied NPs significantly decreased in vivo inflammation compared to the reference drug in a TPA-induced mouse ear edema model. Thus, it was concluded that NPs containing CP may be a useful tool for the dermal treatment of local inflammation.
Collapse
Affiliation(s)
- Alexander Parra
- Department of Pharmacy and Pharmaceutical Technology, Biopharmaceutics and Pharmacokinetics Unit, Faculty of Pharmacy, University of Barcelona, Joan XXIII Avenue, 08028 Barcelona, Spain; Department of Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Joan XXIII Avenue, 08028 Barcelona, Spain
| | - Beatriz Clares
- Department of Pharmacy and Pharmaceutical Technology, University of Granada, Campus de la Cartuja Street, 18071 Granada, Spain.
| | - Ana Rosselló
- Department of Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Joan XXIII Avenue, 08028 Barcelona, Spain
| | - María L Garduño-Ramírez
- Centro de Investigaciones Químicas, Universidad Autónoma del Estado de Morelos, Av. Universidad No. 1001, Col Chamilpa, Cuernavaca, Morelos, Mexico, Mexico
| | - Guadalupe Abrego
- Centro de Investigaciones Químicas, Universidad Autónoma del Estado de Morelos, Av. Universidad No. 1001, Col Chamilpa, Cuernavaca, Morelos, Mexico, Mexico
| | - María L García
- Department of Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Joan XXIII Avenue, 08028 Barcelona, Spain
| | - Ana C Calpena
- Department of Pharmacy and Pharmaceutical Technology, Biopharmaceutics and Pharmacokinetics Unit, Faculty of Pharmacy, University of Barcelona, Joan XXIII Avenue, 08028 Barcelona, Spain
| |
Collapse
|
53
|
Affiliation(s)
- Rob A. Pettitt
- Small Animal Teaching HospitalSchool of Veterinary ScienceUniversity of LiverpoolLeahurst Campus, Chester High RoadNestonWirralCH64 7TEUK
| | - Alexander J. German
- Small Animal Teaching HospitalSchool of Veterinary ScienceUniversity of LiverpoolLeahurst Campus, Chester High RoadNestonWirralCH64 7TEUK
| |
Collapse
|
54
|
Vandeweerd JM, Zhao Y, Nisolle JF, Zhang W, Zhihong L, Clegg P, Gustin P. Effect of corticosteroids on articular cartilage: have animal studies said everything? Fundam Clin Pharmacol 2015. [DOI: 10.1111/fcp.12137] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Jean-Michel Vandeweerd
- Integrated Veterinary Research Unit (IVRU); Namur Research Institute for Life Sciences (NARILIS); University of Namur; Rue de Bruxelles 61 5000 Namur Belgium
| | - Yang Zhao
- Integrated Veterinary Research Unit (IVRU); Namur Research Institute for Life Sciences (NARILIS); University of Namur; Rue de Bruxelles 61 5000 Namur Belgium
- Shanghai Jiaotong University; School of Medicine; 280, South Chongqing road, 200025 Shanghai China
- Service de Pharmacologie-Pharmacothérapie-Toxicologie; Département des Sciences Fonctionnelles, Faculté de Médecine Vétérinaire; Université de Liège, Boulevard de Colonster B41; B-4000 Liège Belgique
| | - Jean-François Nisolle
- Département d'imagerie médicale; Centre Hospitalier Universitaire Mont Godinne-Dinant, Avenue Docteur Gaston-Therasse 1; 5530 Yvoir Belgique
| | - Wenhui Zhang
- Shanghai Jiaotong University; School of Medicine; 280, South Chongqing road, 200025 Shanghai China
| | - Liu Zhihong
- Département d'imagerie médicale; Centre Hospitalier Universitaire Mont Godinne-Dinant, Avenue Docteur Gaston-Therasse 1; 5530 Yvoir Belgique
- Orthopaedics Department, Ruijin Hospital; Shanghai Jiaotong University; School of Medicine, 197, Rui Jin Er Road; 200025 Shanghai China
| | - Peter Clegg
- Department of Musculoskeletal Biology; Faculty of Health and Life Sciences, University of Liverpool, Leahurst Campus; CH64 7TE Neston UK
| | - Pascal Gustin
- Service de Pharmacologie-Pharmacothérapie-Toxicologie; Département des Sciences Fonctionnelles, Faculté de Médecine Vétérinaire; Université de Liège, Boulevard de Colonster B41; B-4000 Liège Belgique
| |
Collapse
|
55
|
Hunt JR, Dean RS, Davis GND, Murrell JC. An analysis of the relative frequencies of reported adverse events associated with NSAID administration in dogs and cats in the United Kingdom. Vet J 2015; 206:183-90. [PMID: 26361747 DOI: 10.1016/j.tvjl.2015.07.025] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Revised: 07/21/2015] [Accepted: 07/23/2015] [Indexed: 12/14/2022]
Abstract
This study aimed to analyse UK pharmacovigilance data to quantify adverse events (AEs) associated with the non-steroidal anti-inflammatory drug (NSAID) molecules found in veterinary medicines authorised for use in dogs and cats. It was hypothesised that the frequency of AEs would be lower when associated with cyclo-oxygenase-2 selective (coxib), compared to non-selective (non-coxib) NSAIDs. The UK Veterinary Medicines Directorate (VMD) supplied frequencies of AEs derived from Periodic Safety Update Reports subdivided by formulation and species for each NSAID molecule. Frequencies of AEs were similar between species. The five most reported AEs were emesis, death, anorexia, lethargy, and diarrhoea. Reported frequency of emesis, renal insufficiency and death was higher with injectable compared to oral NSAIDs (P = 0.043). Reported frequency of emesis, lethargy and death was higher with coxib, compared to non-coxib NSAIDs (P = 0.029). Median (range) interval since authorisation was shorter for coxibs at 5 (2.5-9) years compared to non-coxibs at 15 (12-25) years. A negative correlation between time elapsed since authorisation and the frequency of AEs was identified (rs = -0.11 to -0.94). Higher frequency of reported AEs with injectable NSAIDs may be related to perioperative administration. The AE frequency associated with coxib and non-coxib NSAIDs may be confounded by changes in reporting habits over time. This study highlights the value of interrogating passive surveillance data to identify low frequency AEs and the need to facilitate improvement in recording and collecting AEs in small animal practice.
Collapse
Affiliation(s)
- James R Hunt
- University of Bristol, School of Veterinary Sciences, Langford BS40 5DU, UK.
| | - Rachel S Dean
- Centre for Evidence-based Veterinary Medicine, School of Veterinary Medicine and Science, The University of Nottingham, Sutton Bonington Campus, Leicestershire LE12 5RD, UK
| | - Giles N D Davis
- Pharmacovigilance Unit, Veterinary Medicines Directorate, Woodham Lane, New Haw, Addlestone, Surrey KT15 3LS, UK
| | - Joanna C Murrell
- University of Bristol, School of Veterinary Sciences, Langford BS40 5DU, UK
| |
Collapse
|
56
|
Lascelles BDX, Knazovicky D, Case B, Freire M, Innes JF, Drew AC, Gearing DP. A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain. BMC Vet Res 2015; 11:101. [PMID: 25926287 PMCID: PMC4419463 DOI: 10.1186/s12917-015-0413-x] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2014] [Accepted: 04/17/2015] [Indexed: 12/18/2022] Open
Abstract
Background There is a critical need for proven drugs other than non-steroidal anti-inflammatory drugs for treatment of degenerative joint disease (DJD) pain in dogs. Antibodies against nerve growth factor (NGF) are analgesic in rodent models and in humans with DJD. This pilot study aimed to evaluate the efficacy of a novel caninised anti-NGF antibody (NV-01) for the treatment of DJD pain in dogs. In a randomized, parallel group, stratified, double masked, placebo controlled, proof of principle clinical pilot study design, 26 dogs with DJD received NV-01 (200 mcg/kg IV) or placebo on day 0 (D0). In addition to objective accelerometry measures, owners completed clinical metrology instruments (Client-Specific Outcome Measures [CSOM], Canine Brief Pain Inventory [CBPI] and Liverpool Osteoarthritis in Dogs Index [LOAD]) on D0, D14 and D28. CBPI subscales (pain severity [PS] and pain interference [PI]), CSOM and LOAD scores were evaluated within and between groups for change over time. Recognized success/failure criteria were applied and success compared between groups. Results CBPI PS and PI scores significantly improved in the NV-01 group (PS: D0-14, P = 0.012 and D0-28, P = 0.019; PI: D0-14, P = 0.012 and D0-28, P = 0.032) but not in the placebo group. CSOM scores showed similar patterns with a significant difference between within-group changes at D14 and D28 (P = 0.038 and P = 0.009, respectively), and significantly more successes at D28 (P = 0.047). LOAD scores significantly improved in the NV-01 group (D0-14, P = 0.004 and D0-28, P = 0.002) but not in the placebo group. There were significant differences between the groups for change in LOAD score at D14 (P = 0.014) and D28 (P = 0.033). No side effects were noted. Activity in the NV-01 group increased over the study period compared to placebo (P = 0.063) and the difference between the groups for change in activity over the time period 9am-5pm (8 hours) was significant (P = 0.006). Conclusions These pilot data demonstrate a positive analgesic effect of anti-NGF antibody in dogs suffering from chronic pain. The magnitude of the effect appeared identical to that expected with an NSAID. Electronic supplementary material The online version of this article (doi:10.1186/s12917-015-0413-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- B Duncan X Lascelles
- Comparative Pain Research Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA. .,Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA. .,Center for Pain Research and Innovation, UNC School of Dentistry, Chapel Hill, NC, USA.
| | - David Knazovicky
- Comparative Pain Research Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.
| | - Beth Case
- Comparative Pain Research Laboratory, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.
| | - Mila Freire
- Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.
| | | | | | | |
Collapse
|
57
|
Tamura D, Saito T, Murata K, Kawashima M, Asano R. Celecoxib exerts antitumor effects in canine mammary tumor cells via COX‑2‑independent mechanisms. Int J Oncol 2015; 46:1393-404. [PMID: 25571853 DOI: 10.3892/ijo.2015.2820] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Accepted: 12/05/2014] [Indexed: 11/06/2022] Open
Abstract
Celecoxib plays antitumor roles via multiple mechanisms in a variety of human cancers. The aim of this study was to clarify the mechanism of action of celecoxib in canine mammary tumors. We examined the antitumor effects of celecoxib in AZACB canine mammary tumor cells expressing low levels of cyclooxygenase‑2 (COX‑2) to minimize the effect of COX‑2 on its activity. Our data revealed that celecoxib inhibited cell proliferation mainly via COX‑2‑independent mechanisms. Specifically, celecoxib decreased the proportion of cells in S phase and increased G2/M arrest, which was associated with increased expression of the cyclin‑dependent kinase inhibitors (CDKIs) p21 and p27. In addition, treatment with celecoxib downregulated COX‑2 expression, and induced apoptosis via both the intrinsic and extrinsic pathways. These findings suggest that celecoxib might be a useful agent for the treatment of canine mammary tumors, regardless of COX‑2 expression. In the future, it might be possible to use a combination of celecoxib and other antitumor agents to treat canine mammary tumors.
Collapse
Affiliation(s)
- Dai Tamura
- Laboratory of Veterinary Pharmacology, Nihon University College of Bioresource Sciences, Fujisawa, Kanagawa 252‑8510, Japan
| | - Teruyoshi Saito
- Laboratory of Veterinary Pharmacology, Nihon University College of Bioresource Sciences, Fujisawa, Kanagawa 252‑8510, Japan
| | - Kanae Murata
- Laboratory of Veterinary Pharmacology, Nihon University College of Bioresource Sciences, Fujisawa, Kanagawa 252‑8510, Japan
| | - Masafumi Kawashima
- Laboratory of Veterinary Pharmacology, Nihon University College of Bioresource Sciences, Fujisawa, Kanagawa 252‑8510, Japan
| | - Ryuji Asano
- Laboratory of Veterinary Pharmacology, Nihon University College of Bioresource Sciences, Fujisawa, Kanagawa 252‑8510, Japan
| |
Collapse
|
58
|
Pattullo KM, Kidney BA, Taylor SM, Jackson ML. Reticulocytosis in nonanemic dogs: increasing prevalence and potential etiologies. Vet Clin Pathol 2014; 44:26-36. [PMID: 25488123 DOI: 10.1111/vcp.12215] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND An increasing prevalence of reticulocytosis in the absence of anemia (RAA) in dogs has been suspected in recent years. OBJECTIVES The objectives were to determine whether prevalence of RAA in our canine population has been increasing over the last years, and to identify potential predisposing factors. METHODS The annual prevalence of RAA in adult dogs was determined between 2000 and 2012. Clinical histories and CBC data were analyzed for all dogs, as well as owner response to a questionnaire including information on nutrition and supplements was conducted for dogs with RAA identified between 2011 and 2012. In addition, serum iron concentration (Fe), total iron-binding capacity (TIBC), and percent transferrin saturation (%TS) were determined in 14 dogs with RAA and compared with 8 healthy control dogs. RESULTS Reticulocytosis in the absence of anemia was identified in 1035 dogs, with the prevalence increasing since 2006. Dogs with RAA evaluated after 2006 (n = 853) had significantly lower MCV and were more likely to have microcytosis than those prior to 2006 (n = 182). Increased incidence of osteoarthritis was observed in dogs evaluated after 2006, including the dogs studied between 2011 and 2012 (n = 31), and administration of nonsteroidal anti-inflammatory drugs, omega-3 fatty acids, and glucosamine was more common in the latter. Significantly lower mean Fe and %TS, and higher TIBC were found in dogs with RAA compared to unaffected dogs. CONCLUSIONS Prevalence of RAA has increased in recent years in our canine population. More ubiquitous use of anti-inflammatory medications and nutraceuticals, associated with increased diagnosis of osteoarthritis should be considered as contributing factors.
Collapse
Affiliation(s)
- Kimberly M Pattullo
- Department of Veterinary Pathology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada
| | | | | | | |
Collapse
|
59
|
Payne-Johnson M, Becskei C, Chaudhry Y, Stegemann MR. Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis. Vet Rec 2014; 176:284. [PMID: 25433056 PMCID: PMC4392193 DOI: 10.1136/vr.102397] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A multi-site, masked, randomised parallel group study employing a double dummy treatment design was performed in canine veterinary patients to determine the comparative efficacy and safety of mavacoxib and carprofen in the treatment of pain and inflammation associated with osteoarthritis for a period of 134 days. Treatments were administered according to their respective summaries of product characteristics. Of 139 dogs screened, 124 were suitable for study participation: 62 of which were dosed with mavacoxib and 62 with carprofen. Both treatments resulted in a very similar pattern of considerable improvement as indicated in all parameters assessed by both owner and veterinarian. The primary efficacy endpoint ‘overall improvement’ was a composite score of owner assessments after approximately six weeks of treatment. Both drugs were remarkably effective, with 57/61 (93.4 per cent) of mavacoxib-treated dogs and 49/55 (89.1 per cent) of carprofen-treated dogs demonstrating overall improvement and with mavacoxib's efficacy being non-inferior to carprofen. The treatments had a similar safety profile as evidenced by documented adverse events and summaries of clinical pathology parameters. The positive clinical response to treatment along with the safety and dosing regimen of mavacoxib makes it an attractive therapy for canine osteoarthritis.
Collapse
Affiliation(s)
| | - C Becskei
- Veterinary Medicine Research & Development Zoetis Inc, Mercuriusstraat 20, Zaventem B-1930, Belgium
| | - Y Chaudhry
- Veterinary Medicine Research & Development Zoetis Inc, Mercuriusstraat 20, Zaventem B-1930, Belgium
| | - M R Stegemann
- Veterinary Medicine Research & Development Zoetis Inc, Mercuriusstraat 20, Zaventem B-1930, Belgium
| |
Collapse
|
60
|
Lees P, Pelligand L, Elliott J, Toutain PL, Michels G, Stegemann M. Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review. J Vet Pharmacol Ther 2014; 38:1-14. [DOI: 10.1111/jvp.12185] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Accepted: 10/19/2014] [Indexed: 12/22/2022]
Affiliation(s)
- P. Lees
- Department of Comparative Biomedical Sciences; Royal Veterinary College; Hatfield Herts UK
| | - L. Pelligand
- Department of Comparative Biomedical Sciences; Royal Veterinary College; Hatfield Herts UK
| | - J. Elliott
- Department of Comparative Biomedical Sciences; Royal Veterinary College; Hatfield Herts UK
| | - P.-L. Toutain
- École National Vétérinaire de Toulouse; INRA; UMR 1331 Toxalim 23 Chemin des Capelles-BP 87614; Toulouse Cedex France
| | - G. Michels
- Zoetis; Global Development & Operations; Veterinary Medicine Research & Development; Kalamazoo MI USA
| | - M. Stegemann
- Zoetis; Global Development & Operations; Veterinary Medicine Research & Development; Zaventem Belgium
| |
Collapse
|
61
|
Donnell JR, Frisbie DD. Use of firocoxib for the treatment of equine osteoarthritis. VETERINARY MEDICINE-RESEARCH AND REPORTS 2014; 5:159-168. [PMID: 32670856 PMCID: PMC7337192 DOI: 10.2147/vmrr.s70207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Accepted: 04/23/2014] [Indexed: 11/23/2022]
Abstract
This review presents the pathogenesis and medical treatment of equine osteoarthritis (OA), focusing on firocoxib. Inhibition of prostaglandin E2 remains a fundamental treatment for decreasing clinical symptoms (ie, pain and lameness) associated with OA in horses. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the production of prostaglandin E2 from the arachidonic acid pathway, continue to be a mainstay for the clinical treatment of OA. Firocoxib is a cyclooxygenase (COX)-2-preferential NSAID that has been shown to be safe and to have a 70% oral bioavailability in the horse. Three clinical reports identified symptom-modifying effects (reduction in pain and/or lameness) in horses with OA administered the once-daily recommended dose (0.1 mg/kg) of oral firocoxib following 7 days of administration. Other reports have suggested that a one-time loading dose (0.3 mg/kg) of firocoxib provides an earlier (1–3 days) onset of action compared to the recommended dose. It is noteworthy that OA disease-modifying effects have been reported in horses for other COX-2-preferential NSAIDs (meloxicam and carprofen), but have not been attributed to firocoxib due to a lack of investigation to date.
Collapse
Affiliation(s)
- Josh R Donnell
- Department of Clinical Sciences, Orthopedic Research Center, Colorado State University, Fort Collins, CO, USA
| | - David D Frisbie
- Department of Clinical Sciences, Orthopedic Research Center, Colorado State University, Fort Collins, CO, USA
| |
Collapse
|
62
|
Marycz K, Śmieszek A, Grzesiak J, Nicpoń J. Effects of steroids on the morphology and proliferation of canine and equine mesenchymal stem cells of adipose origin - in vitro research. Acta Vet Hung 2014; 62:317-33. [PMID: 24659718 DOI: 10.1556/avet.2014.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Disorders of the locomotive system, especially those occurring due to degenerative changes of the joints, are serious problems in daily veterinary medical practice. Steroid injections are the main way of treating these disorders. However, this approach brings usually only temporary effects of pain relief, and may cause many side effects. Alternative therapies focus on regeneration of damaged tissue using adult mesenchymal stem cells (MSCs). Since 2002, the great plasticity and immunomodulatory properties of MSCs isolated from adipose tissue (AdMSCs) have been used successfully in the treatment of degenerative joint diseases (DJD) of both dogs and horses. Possible simultaneous application of steroid therapy and stem cell transplantation could improve the commonly used clinical procedure. In this paper, the influence of the two steroid drugs (betamethasone and methylprednisolone) on AdMSCs was evaluated on the basis of morphology and proliferation rate. Both steroids positively influenced the viability and proliferation state of cells in a concentration of 0.01 mg/ml and 0.1 mg/ml, respectively. However, the concentration of 1 mg/ml had a cytotoxic effect. Moreover, the lower dosage of steroid drugs used in the experiment did not affect the morphology of cells and significantly increased cellular activity. In conclusion, our data demonstrate the stimulating effect of steroid drugs on cell morphology, proliferation rate and cytophysiological activity. These findings may influence the use of stem cells and steroids in applied regenerative veterinary medical practice in the future.
Collapse
Affiliation(s)
- Krzysztof Marycz
- 1 University of Environmental and Life Sciences Wroclaw Electron Microscopy Laboratory Kozuchowska 5b 51-631 Wroclaw Poland
| | - Agnieszka Śmieszek
- 1 University of Environmental and Life Sciences Wroclaw Electron Microscopy Laboratory Kozuchowska 5b 51-631 Wroclaw Poland
| | - Jakub Grzesiak
- 1 University of Environmental and Life Sciences Wroclaw Electron Microscopy Laboratory Kozuchowska 5b 51-631 Wroclaw Poland
| | - Jakub Nicpoń
- 2 Wroclaw University of Environmental and Life Sciences Department of Surgery, Faculty of Veterinary Medicine Wroclaw Poland
| |
Collapse
|
63
|
Walton MB, Cowderoy EC, Wustefeld-Janssens B, Lascelles BDX, Innes JF. Mavacoxib and meloxicam for canine osteoarthritis: a randomised clinical comparator trial. Vet Rec 2014; 175:280. [PMID: 24859353 DOI: 10.1136/vr.102435] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
NSAIDs are the cornerstone of medical management of canine osteoarthritis (OA). Meloxicam is a daily-administered NSAID widely available in a liquid formulation and manufacturer's summary of product characteristics (SPC) advise that it is given at the lowest effective dose. Mavacoxib is a long-acting NSAID given as a monthly tablet. This study compares these drugs in the management of canine OA. In all, 111 dogs with OA of the elbow, hip or stifle were randomly assigned to receive one of these NSAIDs for a 12-week period, and to administer them as per the manufacturer's SPC. Outcomes, including ground reaction forces and three validated clinical metrology instruments, were measured at baseline, 6 and 12 weeks. Improvements were seen in all outcome measures for both groups to a similar degree, and adverse events occurred at a similar rate. There were significant improvements in outcome measures from week 6 to week 12, as well as from baseline. Long-term meloxicam dose was more important than recent dose. Clinical efficacy and adverse event rates are similar for meloxicam and mavacoxib when administered as per their UK SPC. This is relevant information for veterinary surgeons when prescribing NSAID treatment for canine OA.
Collapse
Affiliation(s)
- M B Walton
- Musculoskeletal Biology and Small Animal Teaching Hospital, University of Liverpool, Neston, Cheshire, UK
| | - E C Cowderoy
- Musculoskeletal Biology and Small Animal Teaching Hospital, University of Liverpool, Neston, Cheshire, UK
| | - B Wustefeld-Janssens
- Musculoskeletal Biology and Small Animal Teaching Hospital, University of Liverpool, Neston, Cheshire, UK
| | - B D X Lascelles
- College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA
| | - J F Innes
- Musculoskeletal Biology and Small Animal Teaching Hospital, University of Liverpool, Neston, Cheshire, UK
| |
Collapse
|
64
|
Mathews K, Kronen PW, Lascelles D, Nolan A, Robertson S, Steagall PVM, Wright B, Yamashita K. Guidelines for Recognition, Assessment and Treatment of Pain. J Small Anim Pract 2014; 55:E10-68. [DOI: 10.1111/jsap.12200] [Citation(s) in RCA: 178] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
65
|
Corti L. Nonpharmaceutical Approaches to Pain Management. Top Companion Anim Med 2014; 29:24-8. [DOI: 10.1053/j.tcam.2014.04.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Accepted: 04/02/2014] [Indexed: 11/11/2022]
|
66
|
Heikkilä HM, Hielm-Björkman AK, Morelius M, Larsen S, Honkavaara J, Innes JF, Laitinen-Vapaavuori OM. Intra-articular botulinum toxin A for the treatment of osteoarthritic joint pain in dogs: a randomized, double-blinded, placebo-controlled clinical trial. Vet J 2014; 200:162-9. [PMID: 24675370 DOI: 10.1016/j.tvjl.2014.01.020] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2013] [Revised: 01/27/2014] [Accepted: 01/29/2014] [Indexed: 01/09/2023]
Abstract
The aim of this study was to investigate the efficacy of intra-articular (IA) botulinum toxin A (IA BoNT A) for the treatment of osteoarthritic joint pain in dogs. The study was a placebo-controlled, randomized, double-blinded clinical trial with parallel group design and 12-week follow-up. Thirty-six dogs with chronic lameness due to stifle, hip or elbow osteoarthritis were randomized to receive an IA injection of 30IU of BoNT A or placebo. The main outcome variables were vertical impulse (VI) and peak vertical force (PVF) measured with a force platform, and Helsinki chronic pain index (HCPI). Subjective pain score and the need for rescue analgesics were secondary variables. The response to treatment was assessed as the change from baseline to each examination week. The variables were analyzed by ANOVA with repeated measurements and results were considered statistically significant if P ⩽ 0.05. The improvement from baseline to 12 weeks after baseline was statistically significant in VI, PVF and HCPI in the treatment group (P=0.001, P=0.054 and P=0.053, respectively). Additionally, there were statistically significant improvements in VI in the treatment group at 2, 4 and 8 weeks after baseline (P=0.037, P=0.016 and P=0.016, respectively). The difference between groups in improvement in VI was statistically significant at 12weeks after baseline (P=0.005). There was no significant change in the subjective pain score or in the requirement for rescue analgesics in either group. No major adverse events thought to be related to trial protocol were detected. These results suggest that IA BoNT A has some efficacy in reducing osteoarthritic pain in dogs.
Collapse
Affiliation(s)
- H M Heikkilä
- Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, P.O. Box 57, 00014 University of Helsinki, Finland.
| | - A K Hielm-Björkman
- Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, P.O. Box 57, 00014 University of Helsinki, Finland
| | - M Morelius
- Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, P.O. Box 57, 00014 University of Helsinki, Finland
| | - S Larsen
- Centre for Epidemiology and Biostatistics, Norwegian School of Veterinary Science, P.O. Box 8146 Dep, 0033 Oslo, Norway
| | - J Honkavaara
- Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, P.O. Box 57, 00014 University of Helsinki, Finland
| | - J F Innes
- Department of Musculoskeletal Biology, Institute of Aging and Chronic Disease and School of Veterinary Science, University of Liverpool, Chester High Road, Neston CH64 7TE, UK
| | - O M Laitinen-Vapaavuori
- Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, P.O. Box 57, 00014 University of Helsinki, Finland
| |
Collapse
|
67
|
MacFarlane PD, Tute AS, Alderson B. Therapeutic options for the treatment of chronic pain in dogs. J Small Anim Pract 2014; 55:127-34. [PMID: 24467556 DOI: 10.1111/jsap.12176] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Chronic pain is a widely recognised problem in humans and is being increasingly recognised as a significant problem in dogs. Whilst a large number of therapies are described and utilised to treat chronic pain in dogs, there is a severe shortage of evidence to guide practitioners in selection of treatments. Until more evidence becomes available, practitioners should adopt a cautious approach, utilising licensed treatments first when possible. Non-pharmacological therapies should be incorporated into the chronic pain management plan whenever possible. Given the probable prevalence of chronic pain in dogs there is an urgent need for research to identify effective treatments.
Collapse
Affiliation(s)
- P D MacFarlane
- Langford Veterinary Services, The University of Bristol, Langford, BS40 5DU
| | | | | |
Collapse
|
68
|
Effect of swimming on clinical functional parameters and serum biomarkers in healthy and osteoarthritic dogs. ISRN VETERINARY SCIENCE 2014; 2014:459809. [PMID: 24977044 PMCID: PMC4060742 DOI: 10.1155/2014/459809] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/14/2013] [Accepted: 12/16/2013] [Indexed: 01/08/2023]
Abstract
This study aimed to determine whether swimming could improve function of osteoarthritic joints in canine hip OA. Fifty-five dogs were categorized into three groups. The OA with swimming group (OA-SW; n = 22), the healthy (non-OA; n = 18) with swimming group (H-SW), and the healthy (non-OA; n = 15) without swimming group (H-NSW). All animals were allowed to swim for a total of 8 weeks (2-day period, 3 cycles of swimming for 20 minutes, and resting period for 5 minutes in each cycle). Three ml of blood was collected every 2 weeks for evaluation of the levels of biomarkers for OA, including chondroitin sulfate epitope WF6 (CS-WF6) and hyaluronan (HA). Clinical evaluation of the OA-SW group found that most parameters showed improvement (P < 0.01) at week 8 compared to pretreatment, while pain on palpation was improved (P < 0.01) at week 6. The relative level of serum CS-WF6 in the OA-SW group was found to be significantly different (P < 0.01) at weeks 6 and 8 compared with the preexercise. The levels of serum HA of the H-SW group in weeks 2-8 were significantly (P < 0.01) higher than preexercise. Conclusion, swimming over 2-day period, 8 weeks continually, can improve the function of OA joint.
Collapse
|
69
|
Monteiro-Steagall BP, Steagall PVM, Lascelles BDX. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med 2013; 27:1011-9. [PMID: 23782347 DOI: 10.1111/jvim.12127] [Citation(s) in RCA: 111] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2012] [Revised: 04/08/2013] [Accepted: 05/14/2013] [Indexed: 12/01/2022] Open
Abstract
The aim of this systematic review was to identify, assess, and critically evaluate the quality of evidence of nonsteroidal anti-inflammatory drug (NSAID)-induced adverse effects in dogs. Original prospective studies published in peer-reviewed journals in English (1990-2012) that reported data on the safety of NSAIDs administration in dogs were searched. For each study, design type (I, II, III, or IV) and assessment of quality (+, Ø, -) were rated. For each drug, quantity and consistency rating (***, **, *) and strength of evidence (high, moderate, low, or extremely low) were identified and evaluated. The strength of evidence was defined in terms of how applicable and relevant the conclusions were to the target population. Sixty-four studies met the inclusion criteria. Thirty-five (55%) research studies and 29 (45%) clinical trials were identified. A high strength of evidence existed for carprofen, firocoxib, and meloxicam; moderate for deracoxib, ketoprofen, and robenacoxib; and low for etodolac. Quality and consistency rating were as follows: carprofen (***/***), deracoxib (**/***), etodolac (*/unable to rate), firocoxib (***/**), ketoprofen (**/***), meloxicam (***/***), and robenacoxib (**/**), respectively. Adverse effects were detected in 35 studies (55%) and commonly included vomiting, diarrhea, and anorexia. Three studies (5%) reported a power analysis related to adverse effects of ≥80%. In randomized, placebo-controlled, blinded studies (n = 25, 39%), the incidence of adverse effects was not statistically different between treated and control dogs. Finally, most studies were not appropriately designed to determine the safety of NSAIDs, and involved a healthy nongeriatric population of research dogs.
Collapse
Affiliation(s)
- B P Monteiro-Steagall
- Veterinary Anesthesia Consultancy Services, Rua Cel. Mello de Oliveira, Sao Paulo, Brazil
| | | | | |
Collapse
|
70
|
|
71
|
Affiliation(s)
- John Innes
- Department of Musculoskeletal Biology and Small Animal Teaching Hospital, University of Liverpool, Leahurst Campus, Neston, Cheshire CH64 7TE, UK.
| |
Collapse
|
72
|
A review of translational animal models for knee osteoarthritis. ARTHRITIS 2012; 2012:764621. [PMID: 23326663 PMCID: PMC3541554 DOI: 10.1155/2012/764621] [Citation(s) in RCA: 138] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/10/2012] [Revised: 11/08/2012] [Accepted: 11/26/2012] [Indexed: 11/18/2022]
Abstract
Knee osteoarthritis remains a tremendous public health concern, both in terms of health-related quality of life and financial burden of disease. Translational research is a critical step towards understanding and mitigating the long-term effects of this disease process. Animal models provide practical and clinically relevant ways to study both the natural history and response to treatment of knee osteoarthritis. Many factors including size, cost, and method of inducing osteoarthritis are important considerations for choosing an appropriate animal model. Smaller animals are useful because of their ease of use and cost, while larger animals are advantageous because of their anatomical similarity to humans. This evidence-based review will compare and contrast several different animal models for knee osteoarthritis. Our goal is to inform the clinician about current research models, in order to facilitate the transfer of knowledge from the "bench" to the "bedside."
Collapse
|
73
|
Contrast magnetic resonance imaging for measurement of cartilage glycosaminoglycan content in dogs: a pilot study. Vet Comp Orthop Traumatol 2012; 26:100-4. [PMID: 23172016 DOI: 10.3415/vcot-12-03-0033] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2012] [Accepted: 10/02/2012] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To assess the ability of a contrast-enhanced magnetic resonance imaging (MRI) technique to quantitatively determine glycosaminoglycan content in canine articular cartilage. METHODS Fifty-four full-thickness cartilage discs were collected from the femorotibial and scapulohumeral joints of three adult dogs immediately following euthanasia. One set of discs from each dog was analysed for glycosaminoglycan content using a colourimetric laboratory assay. The remaining position-matched set of discs from contralateral limbs underwent pre- and post-contrast gadolinium-enhanced MRI, using repeated saturation recovery pulse sequences which were used to generate calculated T1 maps of the cartilage discs. Linear regression analysis was then performed relating delayed gadolinium-enhanced MRI T1 calculated signal intensity to the cartilage glycosaminoglycan content normalized to DNA content. Repeatability of triplicate measurements was estimated by calculating the coefficient of variation. RESULTS Mean coefficient of variation estimates for the gadolinium-enhanced MRI T1 signal intensity values for nine sampling sites from three dogs ranged from 5.9% to 7.5%. Gadolinium-enhanced MRI T1 signal intensity was significantly correlated (p <0.05) with normalized glycosaminoglycan content in two dogs (r = 0.79, p = 0.011; r = 0.78, p = 0.048), but not in the third dog (r = 0.53, p = 0.071). CLINICAL SIGNIFICANCE Gadolinium-enhanced MRI assessment of cartilage may be predictive of glycosaminoglycan content and therefore offer an in vivo assessment of changes in cartilage characteristics over time. Additional studies appear indicated to determine the reliability and clinical applicability of gadolinium-enhanced MRI in detecting changes in cartilage over time.
Collapse
|
74
|
Moreau M, Troncy E, Del Castillo JRE, Bédard C, Gauvin D, Lussier B. Effects of feeding a high omega-3 fatty acids diet in dogs with naturally occurring osteoarthritis. J Anim Physiol Anim Nutr (Berl) 2012; 97:830-7. [PMID: 22805303 DOI: 10.1111/j.1439-0396.2012.01325.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The aim of this randomized, placebo-controlled and double-blinded trial was to compare the effect of a veterinary therapeutic diet (VTD) rich in omega-3 fatty acids (omega-3) from fish origin to a regular diet used as control (CTR) over a period of 13 weeks in dogs afflicted by naturally occurring osteoarthritis (OA). Thirty privately owned dogs were selected. Dogs had lameness confirmed by an orthopaedic examination, had stifle/hip OA and had locomotor disability based on the peak of the vertically oriented ground reaction force (PVF) measured using a force platform. At Baseline, all owners were asked to determine 2-5 activities of daily living that were the most impaired. Activities were scores (0-4) in accordance with severity using case-specific outcome measures (CSOM). The PVF was also measured. Dogs (15/group) were then randomly assigned to receive either the CTR or the VTD. The CSOM was completed twice weekly. The recording of PVF was repeated at Week 7 and 13. The VTD-fed dogs showed a significantly higher PVF at Week 7 (p < 0.001) and at Week 13 (p < 0.001) when compared to Baseline. From Baseline to Week 13, VTD-fed dogs had a mean (± SD) change in PVF recording of 3.5 ± 6.8% of body weight (%BW) compared with 0.5 ± 6.1%BW (p = 0.211) in CTR-fed dogs. This change in primary outcome was consistent with an effect size of 0.5. Conversely, dogs fed the CTR did not show significant change in PVF measurements. At the end of the study, the CSOM was significantly decreased (p = 0.047) only in VTD fed dogs. In lame OA dogs, a VTD that contains high level of omega-3 from fish origin improved the locomotor disability and the performance in activities of daily living. Such nutritional approach appears interesting for the management of OA.
Collapse
Affiliation(s)
- M Moreau
- GREPAQ (Research Group in Animal Pharmacology of Quebec), Department of Veterinary Biomedicine, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada Osteoarthritis Research Unit, Université de Montréal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada Department of Pathology and Microbiology, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada, and Department of Clinical Sciences, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada
| | - E Troncy
- GREPAQ (Research Group in Animal Pharmacology of Quebec), Department of Veterinary Biomedicine, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada Osteoarthritis Research Unit, Université de Montréal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada Department of Pathology and Microbiology, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada, and Department of Clinical Sciences, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada
| | - J R E Del Castillo
- GREPAQ (Research Group in Animal Pharmacology of Quebec), Department of Veterinary Biomedicine, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada Osteoarthritis Research Unit, Université de Montréal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada Department of Pathology and Microbiology, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada, and Department of Clinical Sciences, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada
| | - C Bédard
- GREPAQ (Research Group in Animal Pharmacology of Quebec), Department of Veterinary Biomedicine, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada Osteoarthritis Research Unit, Université de Montréal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada Department of Pathology and Microbiology, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada, and Department of Clinical Sciences, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada
| | - D Gauvin
- GREPAQ (Research Group in Animal Pharmacology of Quebec), Department of Veterinary Biomedicine, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada Osteoarthritis Research Unit, Université de Montréal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada Department of Pathology and Microbiology, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada, and Department of Clinical Sciences, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada
| | - B Lussier
- GREPAQ (Research Group in Animal Pharmacology of Quebec), Department of Veterinary Biomedicine, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada Osteoarthritis Research Unit, Université de Montréal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada Department of Pathology and Microbiology, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada, and Department of Clinical Sciences, Faculté de Médecine Vétérinaire, Université de Montréal, Montréal, QC, Canada
| |
Collapse
|
75
|
Vainio O. Translational animal models using veterinary patients - An example of canine osteoarthritis (OA). Scand J Pain 2012; 3:84-89. [PMID: 29913782 DOI: 10.1016/j.sjpain.2011.11.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Accepted: 11/18/2011] [Indexed: 10/28/2022]
Abstract
Background and purpose The use of laboratory animals in pain research has powerfully contributed to our detailed understanding of the physiological mechanisms of pain. Animal models also represent an essential tool to screen and select novel drug molecules with potentially analgesic properties. Despite of the inevitable input of laboratory animal trials, recent studies have shown that animal pain models have repeatedly failed to predict clinical analgesic efficacy and adverse side effects of potential drug molecules in human pain patients. This paper provides a review of the laboratory animal models of OA, which have been developed to test efficacy of novel analgesics. The paper also presents spontaneous OA in canine veterinary patients, and methods to observe chronic pain in nonverbal dogs. Methods PubMed data base was searched as a reference list to locate most relevant articles. A number of 118 articles including 4 reviews were located. Web pages of 4 establishments and 2 private organizations were also accessed. Results The clinical expression and pathogenesis of naturally occurring OA in dogs is considered an analogous disease that occurs in humans, including pain and lameness. OA may occur in any joint in dogs as well as in humans. Primary idiopathic OA in dogs is rare, but certain breeds may be predisposed to it. For the most part, canine OA is considered secondary to acquired or congenital musculoskeletal disorders. Concomitant factors, such as aging and obesity, likely accelerate progression. However, mechanical factors appear to predominate in the etiopathogenesis of canine spontaneous OA. Both subjective (validated questionnaire) and objective (gait analysis) tools are available to measure OA related pain in dogs. Information on the prevalence of canine OA is limited, but rough surveys suggest that 11 million dogs in the United States and 5 million in Europe could suffer from OA. Ethical considerations concerning the use of privately owned dogs can be resolved by a careful experimental design. Conclusion Canine spontaneous OA could serve as a translational animal model that would more closely mimick clinical OA related pain conditions in humans. Privately owned dogs would make a solution to fix the gap between animal pain models and clinical trials when testing potential analgesic drug molecules. Close interdisciplinary cooperation would guarantee that both scientific and ethical intentions would be achieved. Implications The predictability of translational pain research would improve by using privately owned dogs as chronic pain models when testing novel analgesics.
Collapse
Affiliation(s)
- Outi Vainio
- Faculty of Veterinary Medicine, POB 57, 00014 University of Helsinki, Helsinki, Finland
| |
Collapse
|
76
|
Botanical Extracts from Rosehip (Rosa canina), Willow Bark (Salix alba), and Nettle Leaf (Urtica dioica) Suppress IL-1β-Induced NF-κB Activation in Canine Articular Chondrocytes. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2012; 2012:509383. [PMID: 22474508 PMCID: PMC3312281 DOI: 10.1155/2012/509383] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/02/2011] [Revised: 10/27/2011] [Accepted: 11/10/2011] [Indexed: 01/13/2023]
Abstract
The aim of this study was to characterize the anti-inflammatory mode of action of botanical extracts from rosehip (Rosa canina), willow bark (Salix alba), and nettle leaf (Urtica dioica) in an in vitro model of primary canine articular chondrocytes. Methods. The biological effects of the botanical extracts were studied in chondrocytes treated with IL-1β for up to 72 h. Expression of collagen type II, cartilage-specific proteoglycan (CSPG), β1-integrin, SOX-9, COX-2, and MMP-9 and MMP-13 was examined by western blotting. Results. The botanical extracts suppressed IL-1β-induced NF-κB activation by inhibition of IκBα phosphorylation, IκBα degradation, p65 phosphorylation, and p65 nuclear translocation. These events correlated with downregulation of NF-κB targets including COX-2 and MMPs. The extracts also reversed the IL-1β-induced downregulation of collagen type II, CSPG, β1-integrin, and cartilage-specific transcription factor SOX-9 protein expression. In high-density cultures botanical extracts stimulated new cartilage formation even in the presence of IL-1β. Conclusions. Botanical extracts exerted anti-inflammatory and anabolic effects on chondrocytes. The observed reduction of IL-1β-induced NF-κB activation suggests that further studies are warranted to demonstrate the effectiveness of plant extracts in the treatment of OA and other conditions in which NF-κB plays pathophysiological roles.
Collapse
|
77
|
Vandeweerd JM, Coisnon C, Clegg P, Cambier C, Pierson A, Hontoir F, Saegerman C, Gustin P, Buczinski S. Systematic Review of Efficacy of Nutraceuticals to Alleviate Clinical Signs of Osteoarthritis. J Vet Intern Med 2012; 26:448-56. [DOI: 10.1111/j.1939-1676.2012.00901.x] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2011] [Revised: 11/28/2011] [Accepted: 01/26/2012] [Indexed: 11/29/2022] Open
Affiliation(s)
- J.-M. Vandeweerd
- Facultés universitaires Notre-Dame-de-la-Paix; URVI (Unité de Recherche Vétérinaire Intégrée); Namur; Belgique
| | - C. Coisnon
- Facultés universitaires Notre-Dame-de-la-Paix; URVI (Unité de Recherche Vétérinaire Intégrée); Namur; Belgique
| | - P. Clegg
- Department of Musculoskeletal Biology; Faculty of Health and Life Sciences; Leahurst Campus; University of Liverpool; Neston; UK
| | - C. Cambier
- Faculté de Médecine vétérinaire; Université de Liège, Belgique (Secteur de Pharmacologie, Pharmacothérapie et Toxicologie; Département des Sciences Fonctionnelles)
| | - A. Pierson
- Faculté de Médecine vétérinaire; Université de Liège, Belgique (Secteur de Pharmacologie, Pharmacothérapie et Toxicologie; Département des Sciences Fonctionnelles)
| | - F. Hontoir
- Facultés universitaires Notre-Dame-de-la-Paix; URVI (Unité de Recherche Vétérinaire Intégrée); Namur; Belgique
| | - C. Saegerman
- Faculté de Médecine vétérinaire, Université de Liège, Belgique (Research Unit in Epidemiology and Risk Analysis Applied to Veterinary Sciences (UREAR), Department of Infectious and Parasitic Diseases)
| | - P. Gustin
- Faculté de Médecine vétérinaire; Université de Liège, Belgique (Secteur de Pharmacologie, Pharmacothérapie et Toxicologie; Département des Sciences Fonctionnelles)
| | - S. Buczinski
- Faculté de Médecine Vétérinaire; Université de Montréal; Canada
| |
Collapse
|
78
|
Isolation, culture and chondrogenic differentiation of canine adipose tissue- and bone marrow-derived mesenchymal stem cells--a comparative study. Vet Res Commun 2012; 36:139-48. [PMID: 22392598 DOI: 10.1007/s11259-012-9523-0] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/03/2012] [Indexed: 12/29/2022]
Abstract
In the dog, mesenchymal stem cells (MSCs) have been shown to reside in the bone marrow (bone marrow-derived mesenchymal stem cells: BM-MSCs) as well as in the adipose tissue (adipose tissue-derived stem cells: ADSCs). Potential application fields for these multipotent MSCs in small animal practice are joint diseases as MSCs of both sources have shown to possess chondrogenic differentiation ability. However, it is not clear whether the chondrogenic differentiation potential of cells of these two distinct tissues is truly equal. Therefore, we compared MSCs of both origins in this study in terms of their chondrogenic differentiation ability and suitability for clinical application. BM-MSCs harvested from the femoral neck and ADSCs from intra-abdominal fat tissue were examined for their morphology, population doubling time (PDT) and CD90 surface antigen expression. RT-PCR served to assess expression of pluripotency marker Oct4 and early differentiation marker genes. Chondrogenic differentiation ability was compared and validated using histochemistry, transmission electron microscopy (TEM) and quantitative RT-PCR. Both cell populations presented a highly similar morphology and marker expression in an undifferentiated stage except that freshly isolated ADSCs demonstrated a significantly faster PDT than BM-MSCs. In contrast, BM-MSCs revealed a morphological superior cartilage formation by the production of a more abundant and structured hyaline matrix and higher expression of lineage specific genes under the applied standard differentiation protocol. However, further investigations are necessary in order to find out if chondrogenic differentiation can be improved in canine ADSCs using different protocols and/or supplements.
Collapse
|
79
|
Abstract
Hip dysplasia is a common orthopaedic developmental disorder of dogs. This paper reviews the treatment options available for management of the condition in the skeletally immature and adult dog.
Collapse
Affiliation(s)
- A Anderson
- Anderson Abercromby Veterinary Referrals, 1870 Building, Jayes Park Courtyard, Forest Green Road, Ockley, Surrey RH5 5RR
| |
Collapse
|
80
|
Sunaga T, Oh N, Hosoya K, Takagi S, Okumura M. Pro-apoptotic effects of tepoxalin, a cyclooxygenase/lipoxygenase dual inhibitor, on canine synovial fibroblasts. J Vet Med Sci 2012; 74:745-50. [PMID: 22240988 DOI: 10.1292/jvms.11-0435] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Canine osteoarthritis occurs frequently and causes secondary synovitis. Administration of nonsteroidal anti-inflammatory drugs (NSAIDs) is one of the major therapeutic options for pain management of joint diseases. Tepoxalin has an unique property as an NSAIDs that suppresses both cyclooxygenase and lipoxygenase. The purpose of this study was to evaluate antiproliferative effects of tepoxalin on cultured canine synovial cells. Cytotoxic effects of tepoxalin, carprofen, meloxicam and AA-861 on cultured canine synoviocytes were evaluated by MTT colorimetric assay. Apoptosis was detected by morphological observations with Giemsa or annexin V/Hoechst 33342 staining and by the inhibition of caspase-3 activity with N-Ac-Asp-Glu-Val-Asp-CHO (Ac-DEVD-CHO). Cytotoxic effects of tepoxalin were evident in comparison with the effects of carprofen or meloxicam. The same tendency of cytotoxicity was observed when 5-lipoxygenase was inhibited by AA-861. The morphological findings and contradictory effects of Ac-DEVD-CHO with regard to the cytotoxicity proved the proapoptotic effects of tepoxalin. In conclusion, tepoxalin might control osteoarthritic synovitis by inducing apoptosis in proliferating synoviocytes, while most NSAIDs that selectively inhibit cyclooxygenase-2 most likely would not suppress synovial proliferation.
Collapse
Affiliation(s)
- Takafumi Sunaga
- Laboratory of Veterinary Surgery, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18 Nishi 9, Kita-ku, Sapporo, Hokkaido 060-0818, Japan
| | | | | | | | | |
Collapse
|
81
|
Sunaga T, Oh N, Hosoya K, Takagi S, Okumura M. Inhibitory effects of pentosan polysulfate sodium on MAP-kinase pathway and NF-κB nuclear translocation in canine chondrocytes in vitro. J Vet Med Sci 2011; 74:707-11. [PMID: 22214865 DOI: 10.1292/jvms.11-0511] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Pentosan polysulfate sodium (PPS) has a heparin-like structure and is purificated from the plant of European beech wood. PPS has been used for the treatment of interstitial cystitis for human patients. Recent years, it was newly recognised that PPS reduce pain and inflammation of OA. The molecular biological mechanism of PPS to express its clinical effects is not fully understood. The purpose of the present study is to investigate a mechanism of action of PPS on inflammatory reaction of chondrocytes in vitro. It was evaluated that effects of PPS on interleukin (IL)-1β-induced phosphorylation of mitogen-actiated protein kinases (MAPKs), such as p38, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK), nuclear translocation of nuclear factor-kappa B (NF-κB), and matrix metalloproteinase (MMP)-3 production in cultured articular chondrocytes. As a result, in the presence of PPS existence, IL-1β-induced phosphorylation of p38 and ERK were certainly inhibited, while JNK phosphorylation was not affected. Nuclear translocation of NF-κB and MMP-3 production were suppressed by PPS pretreatment prior to IL-1β stimulation. In conclusion, it is strongly suggested that PPS treatment prevents inflammatory intracellular responses induced by IL-1 β through inhibition of phosphorylation of certain MAPKs, p38 and ERK and then nuclear translocation of NF-κB in cultured chondrocytes. These PPS properties may contribute to suppressive consequence of catabolic MMP-3 synthesis. These data might translate the clinical efficacy as PPS treatment could inhibit the cartilage catabolism and related clinical symptoms of OA in dogs.
Collapse
Affiliation(s)
- Takafumi Sunaga
- Laboratory of Veterinary Surgery, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18 Nishi 9, Kita-ku, Sapporo, Hokkaido 060-0818, Japan
| | | | | | | | | |
Collapse
|
82
|
Doré E, Paré J, Côté G, Buczinski S, Labrecque O, Roy JP, Fecteau G. Risk factors associated with transmission of Mycobacterium avium subsp. paratuberculosis to calves within dairy herd: a systematic review. J Vet Intern Med 2011; 26:32-45. [PMID: 22211394 DOI: 10.1111/j.1939-1676.2011.00854.x] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2011] [Revised: 10/18/2011] [Accepted: 11/15/2011] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Paratuberculosis has a worldwide distribution and many countries have implemented control programs to prevent transmission among and within herds. For these programs to be efficient, knowledge of the risk factors involved in transmission is essential. OBJECTIVES Systematically review the scientific literature concerning risk factors associated with Mycobacterium avium subsp. paratuberculosis (MAP) transmission to dairy calves. STUDY DESIGN Systematic review. METHODS An electronic search was done in PubMed and CAB to retrieve references relevant to answer at least 1 of the 5 questions concerning neonatal environment, colostrum, milk, housing of calves, and contact of calves with adult cow feces as risk factors in MAP transmission. A 1st screening was done using titles only, then abstracts, and finally full-length articles were reviewed for relevance. From the articles selected, risk factors and presence of a significant association between these risk factors and MAP transmission were recorded. RESULTS Twenty-three articles from 11 different countries and published in 12 different journals were reviewed. The most common study design was cross-sectional (n = 16). The case definition and diagnostic tests used were very variable among studies, but serum ELISA was used in most studies (n = 14). The study unit was the herd in 18 studies. CONCLUSIONS AND CLINICAL IMPORTANCE The contact of calves with adult cow feces is the most important risk factor in MAP transmission. The 5 categories of risk factors are linked to one another.
Collapse
Affiliation(s)
- E Doré
- Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.
| | | | | | | | | | | | | |
Collapse
|
83
|
Gordon-Evans WJ, Dunning D, Johnson AL, Knap KE. Effect of the use of carprofen in dogs undergoing intense rehabilitation after lateral fabellar suture stabilization. J Am Vet Med Assoc 2011; 239:75-80. [PMID: 21718199 DOI: 10.2460/javma.239.1.75] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To determine whether carprofen, a commercially available NSAID, would decrease perceived exertion and signs of pain in dogs and therefore increase muscle mass and hind limb function without decreasing range of motion after lateral fabellar suture stabilization. DESIGN Randomized, blinded, controlled clinical trial. ANIMALS 35 dogs with cranial cruciate ligament rupture and lateral fabellar suture stabilization followed by rehabilitation. PROCEDURES All dogs underwent surgical stabilization of cranial cruciate ligament rupture by placement of a lateral fabellar suture. Dogs received carprofen (2.2 mg/kg [1 mg/lb], PO, q 12 h) for the first 7 days after surgery and underwent concentrated rehabilitation exercises during weeks 3, 5, and 7 after surgery. Eighteen dogs also received carprofen (2.2 mg/kg, PO, q 12 h) during the weeks of concentrated rehabilitation. Outcomes were measured by a single investigator, who was blinded to group assignments, using pressure platform gait analysis, goniometry, thigh circumference, and mean workout speed at a consistent level of exertion. RESULTS There were no differences between the 2 groups in ground reaction forces, thigh circumference, or exertion (mean workout speed) over time or at any individual time point. However, both groups improved significantly over time for all outcome measures. CONCLUSIONS AND CLINICAL RELEVANCE Providing carprofen to dogs during concentrated rehabilitation after lateral fabellar suture stabilization did not improve hind limb function, range of motion, or thigh circumference, nor did it decrease perceived exertion, compared with control dogs. Carprofen was not a compulsory component of a physical therapy regimen after lateral fabellar suture stabilization.
Collapse
Affiliation(s)
- Wanda J Gordon-Evans
- Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802, USA.
| | | | | | | |
Collapse
|
84
|
Affiliation(s)
- Paul Chambers
- Institute of Veterinary, Animal and Biomedical Sciences; Massey University; Private Bag 11222 Palmerston North New Zealand
| |
Collapse
|
85
|
Clegg PD, Pinchbeck GL. Evidence-based medicine and stem cell therapy: how do we know such technologies are safe and efficacious? Vet Clin North Am Equine Pract 2011; 27:373-82. [PMID: 21872765 DOI: 10.1016/j.cveq.2011.04.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Evidence-based medicine (EBM) refers to the conscientious, explicit, and judicious use of current best evidence from research for the care of an individual patient. Central to the adoption of EBM is both producing and identifying the best possible evidence for a particular intervention or therapy. This article identifies and reviews the approaches to producing and identifying the best possible evidence that is necessary for the full acceptance of stem cell therapies in the horse and reviews the approaches that will allow future clinical studies in stem cell therapies to provide the best evidence for determining efficacy.
Collapse
Affiliation(s)
- Peter D Clegg
- Department of Musculoskeletal Biology, University of Liverpool, Leahurst Campus, Chester High Road, Neston, Cheshire, CH64 7TE, UK.
| | | |
Collapse
|
86
|
Autefage A, Palissier FM, Asimus E, Pepin-Richard C. Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis. Vet Rec 2011; 168:617. [PMID: 21642297 DOI: 10.1136/vr.d1456] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Thirty-nine client-owned dogs with osteoarthritis were treated with 5 mg/kg firocoxib administered orally, once a day for 52 weeks. Veterinary examinations were performed on approximately days 0, 15, 90, 180, 270 and 360. Twenty-five dogs completed the study. The withdrawal rate associated with gastrointestinal side effects was low (5.1 per cent of dogs). Based on the owners' assessment, 82 per cent of the dogs had improved at day 15, 84 per cent of the 32 remaining dogs had improved at day 90, and 96 per cent of the 25 dogs that completed the trial had improved at day 360. During this trial, 12 (48 per cent) of the 25 remaining dogs showed an improvement in their lameness from day 90 to day 360 (P<0.05).
Collapse
Affiliation(s)
- A Autefage
- Unité de Chirurgie, Département des Sciences Cliniques des Animaux de Compagnie, Ecole Nationale Vétérinaire de Toulouse, 23 Chemin des Capelles, BP 87614, 31076 Toulouse Cedex 3, France.
| | | | | | | |
Collapse
|
87
|
Bound NJ, Upjohn MJ, Jackson S, Baines SJ. Assessment of veterinary practitioners in the British Isles' approaches towards the management of canine osteoarthritis. Vet Rec 2011; 168:563. [PMID: 21622617 DOI: 10.1136/vr.d1021] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The aim of this questionnaire-based retrospective study was to ascertain veterinary practitioners in the British Isles' approaches to osteoarthritis in dogs. The Mann-Whitney U test, Kruskal-Wallis test and multiple ordinal logistic regression were used to compare demographic data with treatment options. Questionnaires were returned by 228 practitioners (a response rate of 22.8 per cent). The majority of responses were from males (70 per cent). Eighty-six per cent (188 of 220) of the respondents had graduated from veterinary schools in the UK and Ireland. Veterinarians who had graduated less recently used exercise modulation less frequently (P<0.004, odds ratio [OR]=1.06) and ranked exercise modulation as less important (P=0.008, OR=1.04). Veterinarians who had graduated outside the UK or Ireland were less likely (P=0.033, OR=0.46) to use exercise modulation than those who had graduated in the UK or Ireland. Veterinarians who had graduated more recently were less likely (P=0.008, OR=0.95) to use medications. Female veterinary surgeons were less likely to rank medications as important (P<0.0001, OR=0.29) and less likely to rank corticosteroids as important (P=0.046, OR=0.42) than male veterinary surgeons. Practitioners who had graduated outside the UK or Ireland were less likely (P=0.01, OR=0.30) to rank corticosteroids as important. There was a significant mild negative correlation between the frequency of use of structure-modifying osteoarthritis drugs (SMOADs) and practitioners' opinions on rank importance (-0.32, P<0.0001). Medications such as SMOADs and nutraceuticals were ranked as not important but were used frequently. Overall, age, sex, the university of graduation and the number of canine consultations per day had an impact on the practitioners' treatment protocols.
Collapse
Affiliation(s)
- N J Bound
- Department of Veterinary Clinical Sciences, Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire, UK.
| | | | | | | |
Collapse
|
88
|
Bleedorn JA, Greuel EN, Manley PA, Schaefer SL, Markel MD, Holzman G, Muir P. Synovitis in dogs with stable stifle joints and incipient cranial cruciate ligament rupture: a cross-sectional study. Vet Surg 2011; 40:531-43. [PMID: 21615432 DOI: 10.1111/j.1532-950x.2011.00841.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To evaluate stifle joints of dogs for synovitis, before development of joint instability and cranial cruciate ligament rupture (CrCLR). STUDY DESIGN Cross-sectional study. ANIMALS Dogs (n = 16) with CrCLR and stable contralateral stifles; 10 control dogs with intact CrCL. METHODS Arthritis and tibial translation were graded radiographically. Synovitis severity and cruciate pathology were assessed arthroscopically. Presence of inflammatory cells in synovial membrane biopsies was scored histologically. CrCLR stifle pairs and control stifles were compared. RESULTS Radiographic evidence of arthritis, cranial tibial translation, and arthroscopic synovitis were increased in unstable stifles, when compared with stable contralateral stifles in CrCLR dogs (P < .05). Arthroscopic synovitis in both joints of CrCLR dogs was increased compared with controls, was correlated with radiographic arthritis (S(R) = 0.71, P < .05), and was present in all stable contralateral stifles. Arthroscopically, 75% of stable stifle joints had CrCL fiber disruption, which correlated with severity of synovitis (S(R) = 0.56, P < .05). Histologic evidence of synovitis was identified in all CrCLR dogs, but was only significantly correlated with arthroscopic observations in stable stifles (r(2) = 0.57, P < .005). CONCLUSION Synovitis is an early feature of the CrCLR arthropathy in dogs before development of joint instability clinically. Severity of synovitis is correlated with radiographic arthritis in joints with minimal to no clinically detectable CrCL damage.
Collapse
Affiliation(s)
- Jason A Bleedorn
- Comparative Orthopaedic Research Laboratory, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | | | | | | | | | | | | |
Collapse
|
89
|
McKenzie BA. What is the evidence? There is only very weak clinical trial evidence to support the use of glucosamine and chondroitin supplements for osteoarthritis in dogs. J Am Vet Med Assoc 2011; 237:1382-3. [PMID: 21155677 DOI: 10.2460/javma.237.12.1382] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
90
|
Yeo S, Choe IH, van den Noort M, Bosch P, Lim S. Consecutive acupuncture stimulations lead to significantly decreased neural responses. J Altern Complement Med 2010; 16:481-7. [PMID: 20423216 DOI: 10.1089/acm.2009.0606] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE Functional magnetic resonance imaging (fMRI), in combination with block design paradigms with consecutive acupuncture stimulations, has often been used to investigate the neural responses to acupuncture. In this study, we investigated whether previous acupuncture stimulations can affect brain activations of later acupuncture stimulations. DESIGN All subjects were measured twice in the same scanning session and a block design was used. SETTING The study was conducted at Kyung Hee University, Seoul, Republic of Korea. SUBJECTS Fifteen (15) healthy right-handed male volunteers participated in the study. INTERVENTION The subjects received two acupuncture stimulations on BL62 (Shenmai) on the right foot with a time interval of 5 minutes. In addition, sham stimulations were tested with the same paradigm. OUTCOME MEASURES One-sample t tests were conducted in order to map the brain activations induced by the acupuncture and sham stimulations. Moreover, paired-sample t tests were conducted to investigate the signal changes between the first and second acupuncture stimulation. RESULTS During the first acupuncture stimulation, in the left hemisphere, significant foci of activation were found in the hypothalamus, thalamus, claustrum, cerebellum, inferior frontal gyrus, and the superior temporal gyrus. In the right hemisphere, a significant focus of activation was found in the middle frontal gyrus. In addition, in both hemispheres, a significant focus of activation was found in the inferior parietal lobule. Interestingly, however, during the second acupuncture stimulation, the only areas that were also significantly activated were the cerebellum in the left hemisphere and the inferior parietal lobule in the right hemisphere. CONCLUSIONS We found that consecutive acupuncture stimulations on BL62 affected the neural responses in a significant way, resulting in decreased activations during the second acupuncture stimulation. This is an important finding, suggesting that in future fMRI studies on acupuncture, researchers should take this methodological issue more seriously.
Collapse
Affiliation(s)
- Sujung Yeo
- Research Group of Pain and Neuroscience, WHO Collaborating Centre for Traditional Medicine, East-West Medical Research Institute, Kyung Hee University, Seoul, Republic of Korea
| | | | | | | | | |
Collapse
|
91
|
COX SR, LESMAN SP, BOUCHER JF, KRAUTMANN MJ, HUMMEL BD, SAVIDES M, MARSH S, FIELDER A, STEGEMANN MR. The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs. J Vet Pharmacol Ther 2010; 33:461-70. [DOI: 10.1111/j.1365-2885.2010.01165.x] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
92
|
Thacker EL. Immunomodulators, immunostimulants, and immunotherapies in small animal veterinary medicine. Vet Clin North Am Small Anim Pract 2010; 40:473-83. [PMID: 20471530 DOI: 10.1016/j.cvsm.2010.01.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Immunomodulators, immunostimulants, and immunotherapies are important tools used by veterinary practitioners and researchers to control and direct the immune system of small animals. This article is an overview and summary of some of the most common immunomodulatory agents used in companion animals emphasizing steroidal and nonsteroidal agents, T-cell inhibitors, cytotoxic drugs, immunostimulators and biologic response modifying agents, and neoplasia chemotherapeutic agents.
Collapse
Affiliation(s)
- Eileen L Thacker
- United States Department of Agriculture-Agricultural Research Service, 5601 Sunnyside Avenue, Beltsville, MD 20705-5148, USA.
| |
Collapse
|
93
|
LECOINDRE O, PEPIN-RICHARD C. Tolerance of firocoxib in dogs with osteoarthritis during 90 days. J Vet Pharmacol Ther 2010; 34:190-2. [DOI: 10.1111/j.1365-2885.2010.01227.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
94
|
|
95
|
|
96
|
Innes JF, Clayton J, Lascelles BDX. Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis. Vet Rec 2010; 166:226-30. [PMID: 20173106 DOI: 10.1136/vr.c97] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
The published, peer-reviewed literature was systematically searched for information on the safety and efficacy of long-term (defined as 28 days or more of continuous therapy) NSAID use in the treatment of canine osteoarthritis. Online databases were reviewed in June 2008 and papers were selected based on their relevance. Fifteen papers were identified and evaluated. Six of seven papers indicated a benefit of long-term treatment over short-term treatment in terms of the reduction of clinical signs or lameness; one study showed no benefit. Fourteen papers evaluated safety with calculated experimental (adverse) event rates (EER) between 0 and 0.31, but there was no correlation between study length and EER (rs=-0.109, P=0.793). The balance of evidence for the efficacy of NSAIDs supports longer-term use of these agents for increased clinical effect. There is no indication in the literature that such an approach is associated with a reduction in safety, although robust data on the safety of long-term NSAID use are lacking in large numbers of dogs.
Collapse
Affiliation(s)
- J F Innes
- Small Animal Teaching Hospital and Musculoskeletal Research Group, Faculty of Veterinary Science, University of Liverpool, Leahurst Campus Neston, Wirral CH64 7TE,.
| | | | | |
Collapse
|